| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 43 | 2023 | 6607 | 3.630 |
Why?
|
| Severe Combined Immunodeficiency | 10 | 2024 | 107 | 2.050 |
Why?
|
| Transplantation Conditioning | 13 | 2023 | 2286 | 1.540 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2023 | 79 | 1.510 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 4 | 2020 | 184 | 1.440 |
Why?
|
| Alemtuzumab | 3 | 2021 | 198 | 1.290 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2019 | 71 | 1.250 |
Why?
|
| Graft vs Host Disease | 18 | 2023 | 2734 | 1.100 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 240 | 0.930 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2023 | 363 | 0.900 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2020 | 24 | 0.810 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 45 | 0.800 |
Why?
|
| T-Lymphocytes | 14 | 2024 | 3879 | 0.730 |
Why?
|
| Complement C3b | 1 | 2019 | 10 | 0.720 |
Why?
|
| Thiotepa | 1 | 2020 | 118 | 0.720 |
Why?
|
| Complement Factor B | 1 | 2019 | 13 | 0.710 |
Why?
|
| Complement Pathway, Alternative | 1 | 2019 | 21 | 0.700 |
Why?
|
| Child, Preschool | 28 | 2023 | 16213 | 0.660 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2023 | 180 | 0.650 |
Why?
|
| Unrelated Donors | 6 | 2021 | 319 | 0.650 |
Why?
|
| Bone Marrow Transplantation | 5 | 2017 | 1639 | 0.650 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 405 | 0.620 |
Why?
|
| BK Virus | 2 | 2018 | 123 | 0.610 |
Why?
|
| Organophosphonates | 1 | 2018 | 64 | 0.600 |
Why?
|
| Graft vs Host Reaction | 1 | 2017 | 63 | 0.600 |
Why?
|
| Plasma Exchange | 1 | 2018 | 116 | 0.600 |
Why?
|
| Cytosine | 1 | 2018 | 141 | 0.590 |
Why?
|
| Infant | 25 | 2023 | 13285 | 0.580 |
Why?
|
| Child | 35 | 2023 | 29067 | 0.580 |
Why?
|
| Cystitis | 1 | 2018 | 107 | 0.570 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 137 | 0.570 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 217 | 0.560 |
Why?
|
| Infection Control | 1 | 2018 | 271 | 0.560 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 591 | 0.560 |
Why?
|
| Transplantation, Homologous | 13 | 2023 | 2892 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 603 | 0.510 |
Why?
|
| Tissue Donors | 4 | 2019 | 790 | 0.470 |
Why?
|
| Adolescent | 27 | 2022 | 31239 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2023 | 1234 | 0.400 |
Why?
|
| Virus Diseases | 4 | 2023 | 399 | 0.380 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 1367 | 0.380 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 4787 | 0.350 |
Why?
|
| Neonatal Screening | 4 | 2024 | 165 | 0.350 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 788 | 0.350 |
Why?
|
| Biomarkers | 2 | 2019 | 5055 | 0.350 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2017 | 1765 | 0.340 |
Why?
|
| Infant, Newborn | 14 | 2024 | 8225 | 0.340 |
Why?
|
| Caspase 9 | 3 | 2015 | 189 | 0.330 |
Why?
|
| Immune Reconstitution | 2 | 2018 | 24 | 0.310 |
Why?
|
| Humans | 58 | 2024 | 262248 | 0.310 |
Why?
|
| Allografts | 3 | 2018 | 656 | 0.300 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 939 | 0.290 |
Why?
|
| Gangliosides | 1 | 2007 | 94 | 0.280 |
Why?
|
| Cytomegalovirus | 3 | 2019 | 474 | 0.270 |
Why?
|
| DNA Viruses | 2 | 2017 | 48 | 0.260 |
Why?
|
| Male | 32 | 2022 | 123338 | 0.250 |
Why?
|
| Adoptive Transfer | 2 | 2019 | 447 | 0.240 |
Why?
|
| Leukemia | 4 | 2022 | 1633 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2023 | 38011 | 0.220 |
Why?
|
| Female | 29 | 2020 | 142293 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14913 | 0.210 |
Why?
|
| Lymphopenia | 1 | 2024 | 199 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 67 | 0.200 |
Why?
|
| Early Diagnosis | 1 | 2023 | 302 | 0.200 |
Why?
|
| Thymus Gland | 1 | 2023 | 294 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 334 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 491 | 0.190 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 10 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 479 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 454 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2021 | 250 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 242 | 0.180 |
Why?
|
| Transplant Recipients | 2 | 2020 | 322 | 0.180 |
Why?
|
| Acute Disease | 4 | 2022 | 2431 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.180 |
Why?
|
| Cost of Illness | 1 | 2023 | 503 | 0.170 |
Why?
|
| Complement Activation | 1 | 2019 | 93 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 76 | 0.170 |
Why?
|
| Busulfan | 1 | 2023 | 766 | 0.170 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2011 | 219 | 0.170 |
Why?
|
| Young Adult | 12 | 2022 | 21494 | 0.160 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2018 | 32 | 0.160 |
Why?
|
| Osteoblasts | 2 | 2013 | 362 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 419 | 0.160 |
Why?
|
| Chimerism | 1 | 2018 | 65 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 35 | 0.160 |
Why?
|
| Antigens, Viral | 2 | 2017 | 467 | 0.160 |
Why?
|
| Adult | 14 | 2023 | 78179 | 0.150 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 15 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 336 | 0.150 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 174 | 0.150 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 36 | 0.150 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 162 | 0.150 |
Why?
|
| Pancytopenia | 1 | 2018 | 120 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 29 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2019 | 241 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 706 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 2781 | 0.150 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 68 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 47 | 0.150 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 218 | 0.150 |
Why?
|
| Metapneumovirus | 1 | 2017 | 58 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2017 | 66 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 133 | 0.150 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 389 | 0.150 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 86 | 0.150 |
Why?
|
| Recurrence | 6 | 2023 | 4784 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2018 | 387 | 0.140 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 69 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3080 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 674 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2022 | 555 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2023 | 12923 | 0.130 |
Why?
|
| Cytokines | 2 | 2021 | 2824 | 0.120 |
Why?
|
| Phosphoglucomutase | 1 | 2014 | 9 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 1030 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1958 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 4 | 2023 | 968 | 0.120 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 68 | 0.120 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2014 | 36 | 0.120 |
Why?
|
| Diarrhea | 1 | 2017 | 689 | 0.120 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 34 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 1040 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1041 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 1435 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 777 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 12239 | 0.110 |
Why?
|
| Viruses | 1 | 2014 | 159 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 123 | 0.110 |
Why?
|
| Epitopes | 1 | 2015 | 682 | 0.110 |
Why?
|
| Incidence | 2 | 2023 | 5713 | 0.100 |
Why?
|
| Sibling Relations | 1 | 2011 | 13 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 556 | 0.100 |
Why?
|
| Herpesviridae Infections | 1 | 2013 | 174 | 0.100 |
Why?
|
| Exome | 1 | 2017 | 1234 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 87 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2014 | 351 | 0.100 |
Why?
|
| Pyridines | 1 | 2018 | 1243 | 0.100 |
Why?
|
| Mutation | 4 | 2022 | 15167 | 0.090 |
Why?
|
| Educational Status | 1 | 2011 | 396 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 831 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6104 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1587 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1947 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1868 | 0.090 |
Why?
|
| Organic Chemicals | 3 | 2015 | 113 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2018 | 1479 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 2480 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2020 | 33028 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 907 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2288 | 0.080 |
Why?
|
| Age Factors | 1 | 2018 | 5384 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10021 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 561 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2015 | 3022 | 0.080 |
Why?
|
| Lung | 1 | 2019 | 3167 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 1016 | 0.080 |
Why?
|
| Genotype | 3 | 2023 | 4104 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4745 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 21737 | 0.080 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2007 | 286 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 979 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 4980 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 1072 | 0.060 |
Why?
|
| Risk Factors | 2 | 2017 | 17622 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 1925 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1901 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2013 | 5598 | 0.060 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 136 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2007 | 815 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4768 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 94 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 432 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 214 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1884 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2007 | 766 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 249 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 1642 | 0.050 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 48 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2019 | 55 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 667 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2022 | 399 | 0.040 |
Why?
|
| Melphalan | 1 | 2022 | 834 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2021 | 480 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 491 | 0.040 |
Why?
|
| Quality of Life | 1 | 2011 | 4582 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 91 | 0.040 |
Why?
|
| Heredity | 1 | 2017 | 29 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 147 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 61 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2024 | 7241 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 488 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 178 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 77 | 0.040 |
Why?
|
| Middle Aged | 6 | 2022 | 86544 | 0.040 |
Why?
|
| Milk, Human | 1 | 2019 | 277 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 1534 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 563 | 0.040 |
Why?
|
| Neurons | 1 | 2007 | 2290 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 442 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 410 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1976 | 0.030 |
Why?
|
| Sepsis | 1 | 2020 | 657 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9195 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 972 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 248 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 492 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 46 | 0.030 |
Why?
|
| Siblings | 1 | 2015 | 289 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 1148 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2804 | 0.030 |
Why?
|
| North America | 1 | 2013 | 313 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 146 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 774 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 697 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 866 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 367 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 252 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2397 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 246 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2302 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 1540 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2013 | 259 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 305 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6308 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1684 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2267 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1850 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4337 | 0.020 |
Why?
|
| Animals | 4 | 2020 | 59489 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 1070 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 1145 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 712 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4903 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1416 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1432 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 2041 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2011 | 562 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5724 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 1206 | 0.020 |
Why?
|
| Mice | 3 | 2013 | 34393 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 70367 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 948 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 5071 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6255 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 694 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9282 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 7549 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3347 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5672 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10067 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5538 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2420 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 6927 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 2982 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 12984 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 4126 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 15874 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 4976 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7601 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7545 | 0.010 |
Why?
|